Clinical trials: HIV-infection/Aids
HIV Infections
Safety and Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)
The purpose of this study is to see if giving HIV-positive patients an HIV vaccine plus anti-HIV drugs can help lower HIV levels in the blood (viral load).
- Trial name
- NCT00005001
- Testing
- HIV-1 Immunogen
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Agouron Pharmaceuticals
HIV/AIDS
PlusCare: Mobile Platform to Increase Linkage to Care in Adolescents Living With HIV/AIDS
While major advancements in medical technology over the past decade have significantly improved the life expectancy of persons infected with human immunodeficiency virus (HIV), HIV-positive youth today face new barriers to the…
- Trial name
- NCT03758066
- Testing
- PlusCare
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Dimagi Inc.
HIV Infections
An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients
To compare AS-101 dosing schedules (once a week; 3 times a week; 5 times a week; or 5 times per week on alternate weeks) on the effect on clinical immunology and virus burden in AIDS or AIDS related complex (ARC) patients.
- Trial name
- NCT00002266
- Testing
- AS-101
- Where
- United States
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Sarcoma, Kaposi, HIV Infections
SU5416 in Patients With AIDS-Related Kaposi's Sarcoma Who Have Not Responded to Treatment
The purpose of this study is to test the effectiveness of SU5416 in patients with AIDS-related Kaposi's sarcoma (KS).
- Trial name
- NCT00005931
- Testing
- SU5416
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- SUGEN
HIV Infections
A Study of 1592U89 in HIV-Infected Adults
The purpose of this study is to see if it is safe and effective to give 1592U89 to HIV-positive adults. This study also examines the influence previous anti-HIV treatment has on the effectiveness of 1592U89.
- Trial name
- NCT00002200
- Testing
- Abacavir sulfate
- Where
- United States
- Sponsor
- Glaxo Wellcome
Cytomegalovirus Infections, HIV Infections
A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus
To evaluate the efficacy of oral ganciclovir in preventing progression to cytomegalovirus (CMV) disease (e.g., CMV retinitis, gastrointestinal CMV disease) in CMV-infected people with HIV infection and CD4 lymphocyte counts <=…
- Trial name
- NCT00002095
- Testing
- Ganciclovir
- Where
- 19 sites in United States
- Volunteers
- 700 people
- Sponsor
- Hoffmann-La Roche
Influenza
Further Investigation of an Intramuscular Influenza Vaccine (Multimeric-001)
This is a multi-center, randomized, two stage, double-blind, placebo-controlled administration study comprising 200 healthy participants.
- Trial name
- NCT01146119
- Testing
- Multimeric-001, 500 mcg, Adjuvanted PBS, PBS and TIV 15%
- Where
- 2 sites in Israel
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- BiondVax Pharmaceuticals ltd.
HIV Infection
Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)
To evaluate the safety and efficacy of reformulated raltegravir (MK-0518) 1200 mg once daily in combination with TRUVADA™ versus raltegravir 400 mg twice daily in combination with TRUVADA™ in HIV-1 infected, treatment-naive…
- Trial name
- onceMRK (NCT02131233)
- Testing
- Reformulated Raltegravir, Raltegravir, TRUVADA™
- Volunteers
- 802 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 Drugs
To compare the safety, tolerance, durability of the viral load response and the antiviral activity of the 1592U89/zidovudine(ZDV)/lamivudine (3TC) regimen vs. ZDV/3TC regimen.
- Trial name
- NCT00002391
- Testing
- Abacavir sulfate, Lamivudine, Zidovudine
- Where
- 30 sites in United States
- Sponsor
- Glaxo Wellcome
HIV Infections
The Safety and Effectiveness of Lamivudine Plus Zidovudine, Used With and Without 1592U89, in HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs
To compare the durability of the viral load response following 48 weeks of treatment with 1592U89/lamivudine (3TC)/zidovudine (ZDV) versus 3TC/ZDV alone.
- Trial name
- NCT00002389
- Testing
- Abacavir sulfate, Lamivudine, Zidovudine
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 210 people
- Sponsor
- Glaxo Wellcome
HIV Infections
The Safety and Effectiveness of Zidovudine Plus Acyclovir in Patients With Early HIV Infection
This double-blind, placebo-controlled study is designed to determine the long-term safety and efficacy of concurrent oral Retrovir / Zovirax (AZT and ACV) therapy and oral AZT therapy alone, in the treatment of early symptomatic…
- Trial name
- NCT00002290
- Testing
- Zidovudine, Acyclovir
- Where
- 14 sites in United States
- Sponsor
- Glaxo Wellcome
HIV-1 Infection
Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults
The primary objective of this study is to evaluate the non-inferiority of switching to emtricitabine/rilpivirine/tenofovir alafenamide (FTC/RPV/TAF) fixed dose combination (FDC) as compared to continuing the non-nucleoside…
- Trial name
- NCT02345226
- Testing
- FTC/RPV/TAF, EFV/FTC/TDF
- Where
- 117 sites in United States, Belgium and 7 more
- Volunteers
- 881 people
- Sponsor
- Gilead Sciences
HIV-1 Infection, HIV Infections
A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054)
An open-label, 3-period, fixed-sequence study in a panel of 18 HIV-infected patients on MK0518 as part of a stable treatment regimen for HIV.
- Trial name
- NCT01000818
- Testing
- MK0518 (Raltegravir), famotidine, omeprazole
- Volunteers
- 18 people
- Sponsor
- Merck Sharp & Dohme LLC
Hyper-Triglyceridemia
Effect of Omacor on Triglycerides in HIV Infected Subjects
Omacor is likely to decrease lipid parameters in HIV infected subjects. In these subjects the lipid are decrease due to HAART treatment
- Trial name
- NCT00598910
- Testing
- Omacor
- Where
- 5 sites in Germany, United Kingdom
- Volunteers
- 51 people
- Sponsor
- Solvay Pharmaceuticals
HIV, Sexually Transmitted Infections
Addressing Proven Factors in HIV Prevention for Latino Youth
This study tests the effectiveness of the bilingual Health and Success program, which aims to support Latino parents and schools in their efforts to promote the academic success and healthy choices of youth, with the goal of…
- Trial name
- NCT01633879
- Testing
- audio-CD parent education, health and success parent and school
- Volunteers
- 3,400 people, healthy volunteers welcome
- Sponsor
- Education Development Center, Inc.
HIV Infections
The Safety and Effectiveness of HBY 097 Used With or Without AZT in HIV-Infected Patients Who Have Mild or No Symptoms
To obtain preliminary information on the safety, tolerability, and antiretroviral activity of HBY 097 alone or in combination with zidovudine ( AZT ) versus AZT alone. PER 1/19/96 AMENDMENT: AZT monotherapy arm was eliminated.
- Trial name
- NCT00002357
- Testing
- HBY 097, Zidovudine
- Where
- 6 sites in United States
- Volunteers
- 144 people
- Sponsor
- Hoechst Marion Roussel
Sarcoma, Kaposi, HIV Infections
A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4
To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152) and to establish the MTD at each of the different dosing schedules.
- Trial name
- NCT00002137
- Testing
- Tecogalan sodium
- Where
- United States
- Sponsor
- Daiichi Pharmaceuticals
Infection, Human Immunodeficiency Virus
Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing
A phase I absolute bioavailability study of BMS-626529 following oral and intravenous dosing
- Trial name
- NCT02805556
- Testing
- BMS-663068, BMS-626529
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
A Randomized, Double-Blind Active-Controlled, Dose-Ranging Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients
To characterize the safety and efficacy of fixed doses of MDL 28,574A administered alone and in combination with zidovudine ( AZT ) in patients with asymptomatic or mildly symptomatic HIV infection.
- Trial name
- NCT00002151
- Testing
- Celgosivir hydrochloride
- Where
- 24 sites in United States
- Volunteers
- 200 people
- Sponsor
- Hoechst Marion Roussel
HIV Infections
Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients
The general aim is to evaluate the antiviral activity and safety of increasing doses of oral administered RTV-boosted BILR 355 BS (75 mg and 150 mg twice daily) in HIV-1-infected, NNRTI-experienced patients, followed by 28 day…
- Trial name
- NCT00294372
- Testing
- BILR 355 BS
- Where
- 11 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Boehringer Ingelheim